These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 12481157)

  • 1. Recombinant human prolactin improves antitumor effects of murine natural killer cells in vitro and in vivo.
    Sun R; Wei H; Zhang J; Li A; Zhang W; Tian Z
    Neuroimmunomodulation; 2002-2003; 10(3):169-76. PubMed ID: 12481157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effects of recombinant human prolactin in human adenocarcinoma-bearing SCID mice with human NK cell xenograft.
    Zhang J; Sun R; Wei H; Tian Z
    Int Immunopharmacol; 2005 Feb; 5(2):417-25. PubMed ID: 15652770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human prolactin improves engraftment and reconstitution of human peripheral blood lymphocytes in SCID mice.
    Sun R; Zhang J; Zhang C; Zhang J; Liang S; Sun A; Wang J; Tian Z
    Cell Mol Immunol; 2004 Apr; 1(2):129-36. PubMed ID: 16212900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of tumor growth in mice with severe combined immunodeficiency is mediated by heat shock protein 70 (Hsp70)-peptide-activated, CD94 positive natural killer cells.
    Moser C; Schmidbauer C; Gürtler U; Gross C; Gehrmann M; Thonigs G; Pfister K; Multhoff G
    Cell Stress Chaperones; 2002 Oct; 7(4):365-73. PubMed ID: 12653481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses.
    Salagianni M; Lekka E; Moustaki A; Iliopoulou EG; Baxevanis CN; Papamichail M; Perez SA
    J Immunol; 2011 Mar; 186(6):3327-35. PubMed ID: 21317394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated natural killer cells and interleukin-2 promote granulocytic and megakaryocytic reconstitution after syngeneic bone marrow transplantation in mice.
    Siefer AK; Longo DL; Harrison CL; Reynolds CW; Murphy WJ
    Blood; 1993 Oct; 82(8):2577-84. PubMed ID: 8400305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human prolactin promotes human secondary immunoglobulin response in human/SCID mouse chimeras.
    Zhang J; Sun R; Tian Z
    Clin Vaccine Immunol; 2007 Jan; 14(1):60-4. PubMed ID: 17079435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy.
    Imboden M; Murphy KR; Rakhmilevich AL; Neal ZC; Xiang R; Reisfeld RA; Gillies SD; Sondel PM
    Cancer Res; 2001 Feb; 61(4):1500-7. PubMed ID: 11245457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations.
    Evans R; Fuller JA; Christianson G; Krupke DM; Troutt AB
    Cell Immunol; 1997 Jul; 179(1):66-73. PubMed ID: 9259773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antileukemia activity of a natural killer cell line against human leukemias.
    Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
    Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity.
    Lin CY; Chuang TF; Liao KW; Huang YJ; Pai CC; Chu RM
    Cancer Lett; 2008 Dec; 272(2):285-95. PubMed ID: 18760876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic versus syngeneic killer splenocytes as effector cells for the induction of graft-versus-tumor effect.
    Morecki S; Yacovlev E; Gelfand Y; Vilensky A; Slavin S
    Biol Blood Marrow Transplant; 2004 Jan; 10(1):40-8. PubMed ID: 14752778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population dynamics of natural killer cells in the spleen and bone marrow of normal and leukemic mice during in vivo exposure to interleukin-2.
    Christopher FL; Dussault I; Miller SC
    Immunobiology; 1991 Dec; 184(1):37-52. PubMed ID: 1800310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.
    Schmidt-Wolf IG; Negrin RS; Kiem HP; Blume KG; Weissman IL
    J Exp Med; 1991 Jul; 174(1):139-49. PubMed ID: 1711560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experimental study on IL-2- and IL-15 application in allogeneic hematopoietic stem cell transplantation].
    Chen GH; Wu DP; Sun AN; Yang MZ; Wang Y; Tang XW; Chang HR; Feng YF; Zhu ZL
    Zhonghua Xue Ye Xue Za Zhi; 2008 Aug; 29(8):526-30. PubMed ID: 19112915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2
    Chu Y; Nayyar G; Jiang S; Rosenblum JM; Soon-Shiong P; Safrit JT; Lee DA; Cairo MS
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic administration of recombinant interleukin-6 in mice induces proliferation of lymphoid cells in vivo.
    Puri RK; Leland P
    Lymphokine Cytokine Res; 1992 Jun; 11(3):133-9. PubMed ID: 1391232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies.
    Dubois SP; Miljkovic MD; Fleisher TA; Pittaluga S; Hsu-Albert J; Bryant BR; Petrus MN; Perera LP; Müller JR; Shih JH; Waldmann TA; Conlon KC
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33883258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolactin exerts hematopoietic growth-promoting effects in vivo and partially counteracts myelosuppression by azidothymidine.
    Woody MA; Welniak LA; Sun R; Tian ZG; Henry M; Richards S; Raziuddin A; Longo DL; Murphy WJ
    Exp Hematol; 1999 May; 27(5):811-6. PubMed ID: 10340396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.